Jpmorgan Chase & CO Sellas Life Sciences Group, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,789 shares of SLS stock, worth $6,657. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,789Holding current value
$6,657% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.64 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$912,9100.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$695,9690.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$494,9230.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$354,7353.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $23.6M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...